MTOR and renal cell carcinoma: Thus, they proposed a combinatory treatment with Vandetanib that inhibits ABL1-dependent activation of mTOR, and Metformin, promoting AMPK-dependent activation of SIRT1, ultimately inhibiting NRF2 nuclear translocation, as an effective treatment for FH-deficient RCC [22].